Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Common Equity (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Common Equity for 4 consecutive years, with $43.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 8.72% to $43.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.0 million through Dec 2025, up 8.72% year-over-year, with the annual reading at $43.0 million for FY2025, 8.72% up from the prior year.
  • Common Equity hit $43.0 million in Q4 2025 for Coya Therapeutics, up from $27.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $43.0 million in Q4 2025 to a low of -$8.4 million in Q4 2022.
  • Historically, Common Equity has averaged $20.8 million across 4 years, with a median of $27.8 million in 2025.
  • Biggest five-year swings in Common Equity: skyrocketed 1042.04% in 2023 and later dropped 19.7% in 2025.
  • Year by year, Common Equity stood at -$8.4 million in 2022, then soared by 524.56% to $35.6 million in 2023, then rose by 11.06% to $39.6 million in 2024, then rose by 8.72% to $43.0 million in 2025.
  • Business Quant data shows Common Equity for COYA at $43.0 million in Q4 2025, $27.3 million in Q3 2025, and $28.3 million in Q2 2025.